About the Summit

We are witnessing rapidly unfolding efforts to reinvigorate the antibacterial pipeline, improve antimicrobial stewardship and bring the multidrug microbial resistance under control. Industry, academia and government entities are working together on sustainable solutions for the antibiotic resistance crisis. Multidrug-resistant Gram-negative bacteria currently pose the biggest threat and attract the most attention from researchers and policy makers. Novel platforms, screening strategies and new drugs as well as new pathways for clinical development and market access are needed to overcome the current state of emergency associated with multidrug-resistant bacteria. Cambridge Healthtech Institute's Fourth Annual Re-Entering Antibacterial Discovery and Development Summit is designed as a knowledge and experience exchange for the major stakeholders working in this important area. The Summit features two conferences, Antibacterial Discovery and Development (October 18-19) and Targeting Gram-Negative Pathogens (October 19-20), and several short courses.

Cambridge Healthtech Institute encourages attendees to gain further exposure by presenting their work in the poster sessions. To secure a poster board and inclusion in the conference materials, your abstract must be submitted, approved and your registration paid in full by September 22, 2017.

Reasons you should present your research poster at this conference:
• Your poster will be seen by our international delegation, representing leaders from top pharmaceutical, biotech, academic and government institutions
• Receive $50 off your registration
• Your poster abstract will be published in our conference materials

Note: Posters should be portrait orientation, with maximum dimensions of 36 inches wide (3 feet) x 48 inches high (4 feet).

* We reserve the right to publish your poster title and abstract in various marketing materials and products.
Antibacterial Discovery and Development
October 18-19, 2017 | Omni Parker House | Boston, MA

WEDNESDAY, OCTOBER 18
7:30 am Registration and Morning Coffee

DISCOVERY PLATFORMS
8:30 Chairperson’s Opening Remarks
Lynn Silver, Ph.D., Silver Consulting, LLC

8:35 To Kill a Bacterium You Need to Think Like a Bacterium
Eric Brown, Ph.D., Professor, Biochemistry and Biomedical Sciences, McMaster University
Antibiotic drug resistance has reached crisis proportions, principally because modern industrial drug discovery efforts have failed to provide new antibiotics. In the Brown lab, we are investigating enigmatic processes that are essential for the survival of bacterial pathogens and are working to understand these processes in the context of complex cell systems. The Brown research group is also developing creative chemical biology platforms to enable the discovery and characterization of new chemical probes with utility as tools in exploring complex biology. Efforts to date have resulted in new knowledge, platforms, chemical probes and lead compounds for antibacterial research. The ultimate goal of these studies is to contribute fresh directions for new antibacterial therapies.

9:05 Platforms for Natural Product Discovery
Kim Lewis, Ph.D., University Distinguished Professor, Biology; Director of Antimicrobial Discovery Center, Biology, Northeastern University
Screening soil microorganisms for antimicrobials produced most antibiotics currently in use. This Waxman platform was overhyped by the 60s, precipitating the current antimicrobial resistance crisis. Compounds developed since come from ad hoc projects that are not backed up by a discovery platform, resulting in a large probability of program failure. Two platforms in development can produce novel natural product antibiotics – growing previously uncultured bacteria, and turning on silent operons.

9:35 Development of Microbiome Drugs for Preventing Infections by Multidrug Resistant Bacteria
David N. Cook, Ph.D., Executive Vice President of R&D, CSO, Seres Therapeutics, Inc.
A benefit to the host of an intact microbiome is the ability to resist colonization by exogenous pathogens in the gut. Antibiotics can disrupt the gut microbiome and cause dysbiosis that enables bacterial infections. Seres Therapeutics is developing multiple Ecobiotic drug candidates to reduce gut colonization and prevent infection in at-risk patients, including immunocompromised and neutropenic patients. Progress in these programs will be reviewed.

10:05 Antibiotic Collaborative Drug Discovery Secure Data Sharing
With the resurgence of interest in the Antibiotic Drug Discovery field, it is critical that we learn from the past. Not just at the conceptual level, but at the detailed data level too. Towards that end, CDD has curated antibiotic data from Challenges of Antibacterial Discovery. Conceptually, by collaborating together we mimic with ideas and data, the processes bacteria use to transfer genomic and mechanistic information.

10:35 Coffee Break

APPROACHES TO COMBAT MDR
11:05 The Changing Environment and Challenges in Infections by Antibiotic-Resistant Pathogens
Yoav Golan, M.D., MS FIDSA, Attending Physician, Infectious Diseases, Tufts Medical Center
Advanced age, diabetes, and obesity, among other factors, fuel the emergence of hard to treat, polymicrobial and antibiotic resistant infections. Typical polymicrobial infections include intra-abdominal and wound infections. These may require repeated courses of combination antibiotics, which lead to antibiotic resistance and can increases toxicity, intolerability and drug-drug interactions.

Improved infection prevention, better supportive care, and the development of novel broad-spectrum and safe antibiotics are required.

11:35 Affinity Selection–Mass Spectrometry Identifies Antibacterial Agents with Novel Mechanisms of Action from Whole Cell Active Compound Libraries
Katherine Young, MS, Senior Principal Scientist, Richard T. Clark Fellow for Global Health, Infectious Diseases, Merck
The discovery of new antibacterial agents is directly linked to new screening technologies, particularly technologies that can help to eliminate the rediscovery of known or toxic compounds. Affinity Selection—Mass Spectrometry (ALIS) has proven to be a useful tool for identifying target/ hit pairs, particularly when used with compound libraries pre-selected for whole cell inhibition. Novel antibacterial RNA polymerase inhibitor and DHFR anti-Mycobacterium tuberculosis compounds discovered via ALIS will be presented.

12:05 pm The Epitranscriptome as a Source of Targets for Antimicrobial Drug Development
Peter Dedon, Ph.D., Professor, Biological Engineering, Massachusetts Institute of Technology
All forms of RNA in all organisms, including parasites, bacteria and viruses, are post-transcriptionally modified with dozens of chemical structures, all of which have important functions in microbial physiology. In pathogenic bacteria, ribosomal RNA modifications are associated with antibiotic resistance, while recent discoveries in parasites and bacteria reveal the critical role of transfer RNA modifications in survival during infection. This point is illustrated with novel RNA modification targets in mycobacteria.

12:35 Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

1:05 Session Break
EXTENDED-SPECTRUM BETA-LACTAMASE INHIBITORS

1:50 Chairperson's Remarks
Joyce Sutcliffe, Ph.D., Former Senior Vice President, Biology, Tetraphase Pharmaceuticals, Inc.

2:00 Cyclic Boronic Acid BLIs: Novel Class with Untapped Potential
Olga Lomovskaya, Ph.D., Vice President, Infectious Diseases, The Medicines Company
Vaborbactam is a cyclic boronic acid inhibitor of class A and class C beta-lactamases. It is now in clinical development in combination with meropenem. Biochemical and structural studies demonstrated significant mechanistic differences between vaborbactam and diazabicyclooctanes such as avibactam. The follow-on programs have been initiated that are based on the recent discovery of a new series of potent cyclic boronic acid BLIs capable of inhibiting both serine and metallo carbapenemases.

2:30 Fighting Back against MBL Mediated CREs: Development of Metallo-Beta-Lactamase Inhibitors for Use in Combination with Carbapenems
Martin Everett, Ph.D., CSO, Antabio
MBL-mediated CRE are already endemic in many countries and rapidly spreading world-wide. Antabio have identified a potent and selective lead series with excellent drug-like properties which it is moving into development. Lead compounds show broad spectrum potentiation of meropenem against clinical CRE isolates and demonstrate efficacy in animal models of infection.

3:00 Sponsored Presentation (Opportunity Available)

3:30 Refreshment Break in the Exhibit Hall with Poster Viewing

STRATEGIZING ANTIBACTERIAL R&D

4:00 De-Risking Antimicrobial Development
George L. Drusano, M.D., Professor, Director, Institute for Therapeutic Innovation, University of Florida
Dose and schedule choice are the single most important factors in successfully registering a new antimicrobial. Preclinical PK/PD model evaluation to identify exposure targets for effect and toxicity can be employed along with Monte Carlo simulation with human pharmacokinetics to identify doses and schedules that are highly likely to be successful in the Phase II/III environment. This is extremely important for the development of narrow spectrum agents.

4:30 PANEL DISCUSSION: Considerations for the Discovery Scientist
Joyce Sutcliffe, Ph.D., Former Senior Vice President, Biology, Tetraphase Pharmaceuticals, Inc.
• What makes a good hit? What makes a good lead?
• How do you build a screening paradigm?
• How important is a target product profile? When should it be developed?
• What clinical development aspects should be considered in the discovery process? When should they be incorporated?

5:00 Welcome Reception in the Exhibit Hall with Poster Viewing

6:00 Close of Day

6:00 Dinner Short Course Registration*
*(Separate Registration required, see page 9 for details)

6:15 Dinner Short Course

THURSDAY, OCTOBER 19

7:40 am Interactive Breakout Discussion Groups with Continental Breakfast
This session features various discussion groups that are led by a moderator/s who ensures focused conversations around the key issues listed. Attendees choose to join a specific group and the small, informal setting facilitates sharing of ideas and active networking. Continental breakfast is available for all participants. Details on the topics and moderators are available on the conference website.

SPECIFIC PROGRAMS

8:30 Chairperson's Remarks
Eric Carnes, Ph.D., Research Associate Professor, Office of Research, University of Nebraska – Lincoln

8:40 Monoclonal Antibodies for the Prevention of Infectious Disease: Development Program Targeting Staphylococcus aureus
Chris Stevens, M.D., , CMO, Arsanis, Inc.
Present an overview of the discovery and development of ASN100, a pair of monoclonal antibodies, targeting six S. aureus toxins. Phase I data includes the demonstration of ASN100 penetration into the epithelial lining fluid supporting the target of S. aureus pneumonia prevention. Overview of an ongoing Phase II S. aureus pneumonia prevention study in mechanically ventilated patients including assumptions for study design and sample size calculations.

9:00 Design and Synthesis of S-ribosylhomocysteine Analogues
Christiane Chbib, Pharm.D., Ph.D., Assistant Professor, College of Pharmacy, Larkin Health Science Institute
Three novel classes of S-ribosylhomocysteine (SRH) analogues as potential inhibitors of S-ribosylhomocysteinase (LuxS enzyme) and AI-2 modulators of quorum sensing were developed.
9:20 Antivirulents: Can Bacterial Infections Be Cleared without Antibiotics?
Menachem Shoham, Ph.D., Associate Professor, Biochemistry, Case Western Reserve University
Antivirulents represent an attractive alternative to antibiotics. These agents disarm pathogens of disease-causing toxins without killing them, thereby eliminating survival pressure to develop resistance. Small-molecule F19 is a broad-spectrum antivirulent that inhibits toxin formation in gram-positive pathogens by blocking transcription factor AgrA from binding to its cognate promoter DNA.

9:40 A Flexible, Modular Nanoparticle System for the Treatment of Emerging Infectious Diseases
Eric Carnes, Ph.D., Research Associate Professor, Office of Research, University of Nebraska – Lincoln
Given the arduous development of new antibiotics, a modular nanoparticle system has been developed to help increase efficacy of currently-approved antibiotics. Utilizing the high surface area of mesoporous silica nanoparticles allows for antibiotics to be loaded within the particles to extremely high local concentrations. Encasing these drug-loaded nanoparticles within a lipid bilayer provides a biocompatible interface to allow for targeted and triggered release of the drug cargo.

10:00 Sponsored Presentation (Opportunity Available)

10:30 Coffee Break in the Exhibit Hall with Poster Viewing

PLENARY SESSION: MONEY, COLLABORATION, POLICY

11:10 Chairperson's Remarks
Melissa Stundick, Ph.D., Head of Strategic Alliances, Spero Therapeutics

11:15 SERIES OF BRIEF PRESENTATIONS
Driving Re-Investment in Antibiotics: Update from Europe’s DRIVE-AB
Kevin Outterson, Professor of Law, Boston University & Executive Director, CARB-X
DRIVE-AB has spent three years evaluating economic incentives to rekindle antibiotic R&D (www.drive-ab.eu), funded by the European Union with matching contributions from EFPIA companies. Final results and recommendations from DRIVE-AB will be presented.

Venture Capitalists: What Are Investors Looking For?
Vikas Goyal, Associate, SR One

CARB-X: What Does It Mean to be Powered by CARB-X?
Tyler Merkeley, CARB-X Co-Founder, BARDA’s CARB-X Program Manager, U.S. Department of Health and Human Services (HHS), Biomedical Advanced Research and Development Authority (BARDA)
CARB-X is a global innovation fund to support antibacterial product development supported by the Biomedical Advanced Research and Development Authority (BARDA), National Institute of Allergy and Infectious Diseases and Wellcome Trust, the UK-based global charitable foundation dedicated to improving health. Co-founder, Tyler Merkeley, will share BARDA’s continued vision for CARB-X as the “Global Innovation Fund” to address antibiotic resistant infections, highlight the Powered by CARB-X portfolio, and discuss future partnerships and funding opportunities.

Update on Pathways & Policies to Facilitate Antibiotic Development
Nicole Mahoney, Director, Global Policy, Merck
Antibiotic resistance continues to be a focus for policy makers determined to ensure the continued availability of effective treatments for patients with serious infections. This talk will provide an update on recent discussions with an emphasis on regulatory developments.

12:15 pm PANEL DISCUSSION: Non-Scientific Solutions to Advance Antimicrobial Pipeline
Moderator: Melissa Stundick, Ph.D., Head of Strategic Alliances, Spero Therapeutics
Panelists: Speakers of the Session
1. Lessons learned from the PDUFA process
2. A discussion of near to mid-term priority shifts in policy and non-diluted funding
3. Policy coordination between the US and EU
4. Non-diluted funding: challenges and opportunities

1:00 Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

1:30 Close of Conference
THURSDAY, OCTOBER 19

10:30 am Registration

PLENARY SESSION: MONEY, COLLABORATION, POLICY

11:10 Chairperson's Remarks
Melissa Stundick, Ph.D., Head of Strategic Alliances for Spero Therapeutics

11:15 Series of Brief Presentations

Driving Re-Investment in Antibiotics: Update from Europe's DRIVE-AB
Kevin Otterson, Professor of Law, Boston University & Executive Director, CARB-X
DRIVE-AB has spent three years evaluating economic incentives to rekindle antibiotic R&D (www.drive-ab.eu), funded by the European Union with matching contributions from EFPIA companies. Final results and recommendations from DRIVE-AB will be presented.

Venture Capitalists: What Are Investors Looking For?
Vikas Goyal, Associate, SR One

CARB-X: What Does It Mean to be Powered by CARB-X?
Tyler Merkeley, CARB-X Co-Founder, BARDA's CARB-X Program Manager, U.S. Department of Health and Human Services (HHS), Biomedical Advanced Research and Development Authority (BARDA)
CARB-X is a global innovation fund to support antibacterial product development supported by the Biomedical Advanced Research and Development Authority (BARDA), National Institute of Allergy and Infectious Diseases and Wellcome Trust, the UK based a global charitable foundation dedicated to improving health. Co-Founder, Tyler Merkeley, will share BARDA's continued vision for CARB-X as the “Global Innovation Fund” to address antibiotic resistant infections, highlight the Powered by CARB-X portfolio, and discuss future partnerships and funding opportunities.

Update on Pathways & Policies to Facilitate Antibiotic Development:
Nicole Mahoney, Director, Global Policy, Merck
Antibiotic resistance continues to be a focus for policy makers determined to ensure the continued availability of effective treatments for patients with serious infections. This talk will provide an update on recent discussions with an emphasis on regulatory developments.

12:15 pm PANEL DISCUSSION: Non-Scientific Solutions to Advance Antimicrobial Pipeline
Moderator: Melissa Stundick, Ph.D., Head of Strategic Alliances for Spero Therapeutics
Panelists: Speakers of the Session
1. Lessons learned from the PDUFA process
2. A discussion of near to mid-term priority shifts in policy and non-diluted funding
3. Policy coordination between the US and EU
4. Non-diluted funding: challenges and opportunities

1:00 Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

1:30 Session Break
3:05 Building an Understanding of Porin-Permeation in Gram-Negative Pathogens
Ruben Tommasi, Ph.D., CSO, Entasis

To address the knowledge gap in understanding Gram-negative permeation, we developed a sensitive and specific whole-cell approach in *Escherichia coli* called titratable outer membrane permeability assay system (TOMAS). We used TOMAS to characterize the structure porin-permeation relationships of a set of novel carbapenem analogues through the Pseudomonas aeruginosa porin OprD. Our results suggest that small structural modifications, especially the number and nature of charges and hydrogen bonding groups and their position, have dramatic effects on the ability of these molecules to permeate into cells through OprD.

3:35 Sponsored Presentation (Opportunity Available)

4:05 Refreshment Break with Exhibit and Poster Viewing

4:35 Disrupting the Gram-Negative Outer Membrane
Lee Swem Ph.D., Senior Vice President, CSO, Achaogen

The outer-membrane is a formidable barrier that protects gram-negative bacteria from antibacterial assault. We are focused on identifying compounds that compromise the integrity of the gram-negative outer-membrane. Specifically, we are developing potent small molecule inhibitors of the essential LPS biosynthetic protein, LpxC. In addition, we have developed a rare antibody discovery platform to identify antibodies that inhibit the essential functions of proteins found in the outer-membrane, necessary for its biogenesis.

5:05 Permeability Barriers of Gram-Negative Pathogens and Approaches to Bypass Them
Helen Zgurskaya, Ph.D., Professor, Chemistry and Biochemistry, University of Oklahoma

Gram-negative bacteria are intrinsically resistant to many antibiotics. The problem is broadly recognized and tackled at fundamental and applied levels. The major obstacle in discovery and development of antibiotics effective against such pathogens is the low permeability barrier of Gram-negative pathogens. This presentation will discuss ongoing efforts to understand molecular bases of this barrier and specific strategies to break it in order to achieve potent activities against difficult Gram-negative bacteria.

5:35 Close of Day

5:45 Dinner Short Course Registration* *(Separate Registration required, see page 9 for details)

6:00 Dinner Short Course

THERAPEUTIC APPROACHES

8:30 Chairperson’s Remarks
Todd A. Black, Ph.D., Executive Director, Infectious Diseases, Basic Research, Merck Research Laboratories

8:35 Filling in the Gaps in the MDR Gram-Negative Pipeline
Todd A. Black, Ph.D., Executive Director, Infectious Diseases, Basic Research, Merck Research Laboratories

Antibiotic-resistant Gram-negative bacteria are increasing in prevalence. Some strains are now resistant to all classes of antibiotics, including polymyxins. The discovery of new classes of agents that are effective against Gram-negative pathogens have thus far proven to be an insurmountable challenge despite years of intensive efforts. The recent development of compounds that address specific subsets of resistance mechanisms have thus far been the only effective response. However, this approach provides only incremental improvements in strain coverage and presents challenges identifying the right patients and strategies to ensure appropriate use to reduce rapid development of resistance.

9:05 TP-6076, A Novel Fluorocycline Antibiotic with Potent Activity against Carbapenem-Resistant Gram-Negative Isolates
Jacques Dumas, Ph.D., CSO, Tetraphase Pharmaceuticals, Inc.

Tetraphase (NASDAQ:TTPH), a clinical-stage biopharmaceutical company, is currently developing TP-6076 as a novel, synthetic, fluorocycline antibiotic. TP-6076 is derived from Tetraphase’s proprietary chemistry technology platform and shows high potency against clinically important Gram-negative pathogens, including carbapenem-resistant Acinetobacter baumannii and Enterobacteriaceae. TP-6076 is in Phase I clinical trials, with the goal of addressing serious and life-threatening bacterial infections, including those caused by pathogens otherwise resistant to current treatment options. In this talk, we review the synthesis, in vitro and in vivo activity of TP-6076, as well as the human data available to date. The ongoing development of TP-6076 will be supported by the CARB-X initiative.

9:35 Sponsored Presentation (Opportunity Available)

10:05 Coffee Break

10:35 A Novel Agent for Treatment of Carbapenem-Resistant Enterobacteriaceae
Folkert Reck, Senior Investigator II, Global Discovery Chemistry, Infectious Diseases, Novartis

This presentation will feature a detailed case study of discovery and preclinical assessment of a novel agent for treatment of carbapenem-resistant enterobacteriaceae.
11:05 Discovery of a Novel Class of Gram-Negative Antibiotics
Peter Smith, Ph.D., Scientist, Infectious Disease at Genentech
Multidrug resistant bacteria are emerging and disseminating at alarming rates, and novel classes of Gram-negative antibiotics are desirable to address this growing threat. Through rigorous chemical optimization, we have transformed a novel lead scaffold displaying only weak Gram-positive activity into a molecule with potent activity, in vitro and in vivo, against MDR Gram-negative pathogens. This molecule may ultimately lead to novel therapies to treat the growing threat of Gram-negative resistance.

11:35 The Use of Target-Based Screening to Discover Novel Antibiotic Scaffolds against Multi-Drug Resistant (MDR) Gram-Negative Pathogens
Ramani Varanasi, President & CEO, X-Biotix Therapeutics, Inc.
Despite years of intensive efforts, the discovery of truly novel classes of agents that are effective against MDR pathogens have proven to be a challenge. By combining a multi-target screening campaign against a DNA-encoded library of over 200 billion compounds, focusing our synthetic efforts on compounds consistent with the property space of active Gram-negative antibiotics, and using a whole-cell screening assay (MIC) in multiple Gram-negative bacterial species to rapidly validate activity, we are discovering novel scaffolds that will lead to effective, new antibiotics.

12:05 pm Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

BIOLOGICS FOR GRAM NEGATIVES

1:30 Chairperson's Remarks
Patricia A. Bradford, Ph.D., Antimicrobial Development Specialists, LLC

1:40 Fully Human Antibacterial Monoclonal Antibodies for the Treatment of Acute Pneumonia
Vu Truong, Ph.D., CEO, Aridis Pharmaceuticals Inc.
Anti-infective immunotherapy using human monoclonal antibody (mAb) is a promising approach that is being explored by an increasing number of researchers. We have a human mAb discovery platform that allows for rapid discovery and manufacture of fully human monoclonal antibodies from patients, and are developing several antibacterial antibodies as adjunctive immunotherapy to standard of care antibiotics. Clinical data on Aridis’ mAb programs and our future directions will be presented.

2:10 MEDI3902: An Alternative Treatment for MDR P. aeruginosa
Bret Sellman, Ph.D., Director, Department of Infectious Diseases and Vaccines, MedImmune
Broad-spectrum antibiotic therapy has fueled the current antibiotic resistance epidemic. Taken together with the recent understanding of the adverse effects of antibiotic therapy on the healthy microbiome, pathogen specific therapies (i.e. monoclonal antibodies, mAbs) are being considered as alternatives to empiric broad-spectrum antibiotics for multidrug resistant pathogens such as Pseudomonas aeruginosa. In this presentation, I will discuss promising mAb-based methods for the prevention and treatment of serious P. aeruginosa infections.

2:40 CO-PRESENTATION: Antisense Approaches for Treating Multidrug-Resistant Pathogens
David Greenberg, M.D., Associate Professor of Infectious Diseases and Microbiology Internal Medicine, University of Texas Southwestern
Raymond Schuch, Ph.D., Vice President of Research, Anti-Infectives, Sarepta Therapeutics, Inc.
The rapid rise in antibiotic resistance worldwide illustrates the need for new paradigms in antimicrobial development. We have developed novel species-specific gene-specific therapeutics utilizing antisense technologies (peptide-conjugated phosphorodiamidate morpholino oligomers; PPMOs). We have developed lead PPMOs in numerous drug-resistant gram-negative pathogens that demonstrate activity both in vitro and in vivo infection models. We will review the different targeting strategies that are used with this platform technology.

3:10 Recombinant Lysins as Potent and Novel Anti-Infectives
Raymond Schuch, Ph.D., Vice President of Research, Microbiology, ContraFect Corporation
ContraFect is the leader in the discovery and development of lysins, an innovative approach to treat bacterial infections. Lysins are purified recombinant proteins that act on the cell wall of bacterial pathogens, resulting in lysis on contact and multi-log-fold killing. CF-301, ContraFect’s most advanced product candidate, is a lysin with potent bactericidal activity against Staphylococcus aureus. ContraFect is also engineering lysins against Gram-negative pathogens including Pseudomonas aeruginosa.

3:40 Q&A with the Speakers of the BIOLOGICS FOR GRAM NEGATIVES Session

4:00 Close of Conference
TUESDAY, OCTOBER 17
DINNER SHORT COURSE | 6:00 - 9:00 PM

SC1: Clinically Relevant Animal Modeling for the Evaluation of Novel Antibacterial Approaches
Daniel V. Zurawski, Ph.D., Senior Scientist/Principal Investigator, Clinical RM, Inc., Walter Reed Army Institute of Research
Joseph C. Wenke, Ph.D., U.S. Army Institute of Surgical Research
Mark Shirtliff, Ph.D., Professor, University of Maryland

WEDNESDAY, OCTOBER 18
DINNER SHORT COURSE | 6:15 - 9:15 PM

SC2: From “White Powder” to Drug: The Path from Antibacterial Discovery to the Clinic
Lynn Silver, Ph.D., Silver Consulting, LLC
Aileen Rubio, Ph.D., Head of Biology, Spero Therapeutics
Joyce Sutcliff, Ph.D., Former Senior Vice President, Biology, Tetraphase Pharmaceuticals, Inc.
Vikas Goyal, Associate, SR One
Nicole Mahoney, Director, Global Policy, Merck

THURSDAY, OCTOBER 19
DINNER SHORT COURSE | 6:00 - 9:00 PM

SC3: Technologies to Assess Permeability in Gram Negative Bacteria
David A. Six, Ph.D., Investigator III, Infectious Diseases, Novartis Institutes for BioMedical Research
Alita A. Miller, Ph.D., Head of Bioscience, Entasis Therapeutics
Sponsorship, Exhibit & Lead Generation Opportunities

CHI offers comprehensive sponsorship packages that can be customized to your company’s objectives and budget. Sponsorship allows you to achieve your objectives before, during, and long after the event. Packages may include podium presentations, exhibit space and branding, as well as the use of delegate lists. Signing on early will maximize your exposure to qualified decision-makers and drive traffic to your website in the coming months.

Podium Presentations – Available within the Main Agenda!
Showcase your solutions to a guaranteed, targeted audience through a 15- or 30-minute podium presentation during a specific conference program, breakfast, lunch, or separate from the main agenda within a pre-conference workshop. Package includes exhibit space, on-site branding, and access to cooperative marketing efforts by CHI. For the luncheon option, lunches are delivered to attendees who are already seated in the main session room. Presentations will sell quickly, so sign on early to secure your talk!

Invitation-Only VIP Dinner/Hospitality Suite
Select specific delegates from the pre-registration list to attend a private function at an upscale restaurant or a reception at the hotel. From extending invitations, to venue to suggestions, CHI will deliver your prospects and help you make the most of this invaluable experience.

One-on-One Meetings
Select your top prospects from the pre-conference registration list. CHI will reach out to your prospects and arrange the meeting for you. A minimum number of meetings will be guaranteed, depending on your marketing objectives and needs. A very limited number of these packages will be sold.

Additional Opportunities Available for Sponsorship Include:
• Conference Tote Bags
• Literature Distribution (Tote Bag Insert or Chair Drop)
• Badge Lanyards
• Program Guide Advertisement
• Product Launch

Looking for additional ways to drive leads to your sales team?
CHI’s Lead Generation Programs will help you to obtain more targeted, quality leads throughout the year. We will mine our database of over 1,000,000 life science professionals to meet your specific needs. We guarantee a minimum of 125 leads per program! Opportunities include:
• White Papers
• Webinar
• Custom Market Research Survey
• Podcasts

Exhibit
Exhibitors will enjoy facilitated networking opportunities with qualified delegates, making it the perfect platform to launch a new product, collect feedback, and generate new leads. Exhibit space sells out quickly, so reserve your booth today!

For more information, please contact:
Uma Patel, Business Development Manager
781-972-1349 | upatel@healthtech.com

Hotel & Travel Information

Omni Parker House
60 School Street
Boston, MA 02108
T: 617-227-8600

Reservations: Go to the travel page of AntibacterialDrugDevelopmentSummit.com

Discounted Room Rate: $309 s/d
Discount Cut-off Date: September 11, 2017

Please visit the travel page of AntibacterialDrugDevelopmentSummit.com for additional information.